PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial

Status

Suspended

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511227-33-00

Acronym

N23LAC

Enrollment

Registered

2024-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Brief summary

The endpoint will be the incidence of DLTs.

Detailed description

To characterise the safety and tolerability of LB−100 and azenosertib. The endpoint is the incidence and severity of AEs and DLTs., To determine the efficacy of the combination LB−100 and azenosertib. The endpoints are the DCR, ORR, PFS, OS and DoR.

Interventions

DRUGazenosertib

DRUGalso known as ZN-c3

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The endpoint will be the incidence of DLTs.	—

Secondary

Measure	Time frame
To characterise the safety and tolerability of LB−100 and azenosertib. The endpoint is the incidence and severity of AEs and DLTs., To determine the efficacy of the combination LB−100 and azenosertib. The endpoints are the DCR, ORR, PFS, OS and DoR.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026